[go: up one dir, main page]

MX2021011351A - Tecnologias utiles para la preparacion de oligonucleotidos. - Google Patents

Tecnologias utiles para la preparacion de oligonucleotidos.

Info

Publication number
MX2021011351A
MX2021011351A MX2021011351A MX2021011351A MX2021011351A MX 2021011351 A MX2021011351 A MX 2021011351A MX 2021011351 A MX2021011351 A MX 2021011351A MX 2021011351 A MX2021011351 A MX 2021011351A MX 2021011351 A MX2021011351 A MX 2021011351A
Authority
MX
Mexico
Prior art keywords
oligonucleotide preparation
technologies
technologies useful
preparation
useful
Prior art date
Application number
MX2021011351A
Other languages
English (en)
Inventor
Chandra Vargeese
David Charles Donnell Butler
Sethumadhavan Divakaramenon
Pachamuthu Kandasamy
Jayakanthan Kumarasamy
Gopal Reddy Bommineni
Mamoru Shimizu
Mohammed Rowshon Alam
Keith Andrew Bowman
Bijay Tilak Bhattarai
Stephany Michelle Standley
Original Assignee
Wave Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wave Life Sciences Ltd filed Critical Wave Life Sciences Ltd
Publication of MX2021011351A publication Critical patent/MX2021011351A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/02Phosphorylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Entre otras cosas, la presente divulgación proporciona tecnologías para la preparación de oligonucleótidos, particularmente para la preparación de oligonucleótidos controlada quiralmente, proporcionando las tecnologías una pureza en bruto y un rendimiento enormemente mejorados, y reduciendo significativamente los costes de fabricación.
MX2021011351A 2019-03-20 2020-03-19 Tecnologias utiles para la preparacion de oligonucleotidos. MX2021011351A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962821423P 2019-03-20 2019-03-20
PCT/US2020/023735 WO2020191252A1 (en) 2019-03-20 2020-03-19 Technologies useful for oligonucleotide preparation

Publications (1)

Publication Number Publication Date
MX2021011351A true MX2021011351A (es) 2021-12-10

Family

ID=72520512

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011351A MX2021011351A (es) 2019-03-20 2020-03-19 Tecnologias utiles para la preparacion de oligonucleotidos.

Country Status (11)

Country Link
US (1) US20230089442A1 (es)
EP (1) EP3941924A4 (es)
JP (1) JP2022525541A (es)
KR (1) KR20210149750A (es)
CN (1) CN113748116A (es)
AU (1) AU2020241559A1 (es)
CA (1) CA3134036A1 (es)
IL (1) IL286487A (es)
MX (1) MX2021011351A (es)
SG (1) SG11202110045PA (es)
WO (1) WO2020191252A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240148947A (ko) 2012-07-13 2024-10-11 웨이브 라이프 사이언시스 리미티드 키랄 제어
JP6268157B2 (ja) 2012-07-13 2018-01-24 株式会社Wave Life Sciences Japan 不斉補助基
CN106068325B (zh) 2014-01-16 2021-07-09 波涛生命科学有限公司 手性设计
RU2708237C2 (ru) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
CN114685589A (zh) 2016-03-13 2022-07-01 波涛生命科学有限公司 用于亚磷酰胺和寡核苷酸合成的组合物和方法
MA45188A (fr) 2016-06-03 2019-04-10 Wave Life Sciences Ltd Oligonucléotides, compositions et méthodes associées
WO2017220751A1 (en) 2016-06-22 2017-12-28 Proqr Therapeutics Ii B.V. Single-stranded rna-editing oligonucleotides
US10941402B2 (en) 2016-09-01 2021-03-09 Proqr Therapeutics Ii B.V. Chemically modified single-stranded RNA-editing oligonucleotides
MA46905A (fr) 2016-11-23 2019-10-02 Wave Life Sciences Ltd Compositions et procédés de synthèse de phosphoramidites et d'oligonucléotides
EP3630789A4 (en) 2017-06-02 2021-06-16 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THEIR USE
WO2018223056A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11718638B2 (en) 2017-06-21 2023-08-08 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
AU2018316159A1 (en) 2017-08-08 2020-02-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2019055951A1 (en) 2017-09-18 2019-03-21 Wave Life Sciences Ltd. OLIGONUCLEOTIDE PREPARATION TECHNOLOGIES
SG11202001783YA (en) 2017-10-12 2020-03-30 Wave Life Sciences Ltd Oligonucleotide compositions and methods thereof
WO2019217784A1 (en) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
AU2020309307B2 (en) * 2019-07-09 2023-03-30 F. Hoffmann-La Roche Ag Process for the deprotection of oligonucleotides
WO2023152371A1 (en) 2022-02-14 2023-08-17 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
WO2024013360A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Chemically modified oligonucleotides for adar-mediated rna editing
AU2023306595A1 (en) 2022-07-15 2025-02-27 Proqr Therapeutics Ii B.V. Oligonucleotides for adar-mediated rna editing and use thereof
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
CN120476207A (zh) 2022-11-24 2025-08-12 ProQR治疗上市公司Ⅱ 反义寡核苷酸治疗遗传性hfe血色素沉着症
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
EP4630553A1 (en) 2022-12-09 2025-10-15 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
CN121039282A (zh) 2023-03-24 2025-11-28 ProQR治疗上市公司Ⅱ 用于治疗神经系统病症的反义寡核苷酸
AU2024246572A1 (en) 2023-03-27 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
TW202516003A (zh) 2023-06-16 2025-04-16 荷蘭商Proqr治療上市公司Ii 用於治療神經退化性疾病之反義寡核苷酸
WO2025015335A1 (en) 2023-07-13 2025-01-16 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
WO2025051946A1 (en) 2023-09-07 2025-03-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2025096809A1 (en) 2023-10-31 2025-05-08 Korro Bio, Inc. Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025104239A1 (en) 2023-11-16 2025-05-22 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
WO2025128799A1 (en) 2023-12-12 2025-06-19 Korro Bio, Inc. Double-stranded rna-editing oligonucleotides and uses thereof
WO2025132708A1 (en) 2023-12-20 2025-06-26 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1549315A4 (en) * 2002-09-11 2007-05-23 Merck & Co Inc DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS
US10428019B2 (en) * 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
KR20240148947A (ko) * 2012-07-13 2024-10-11 웨이브 라이프 사이언시스 리미티드 키랄 제어
JP6268157B2 (ja) * 2012-07-13 2018-01-24 株式会社Wave Life Sciences Japan 不斉補助基
MA43072A (fr) * 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
JP7164540B2 (ja) * 2017-03-29 2022-11-01 ロシュ イノベーション センター コペンハーゲン エーエス 立体的に規定されたホスホロチオエートオリゴヌクレオチドの調製のための直交保護基
US20220306573A1 (en) * 2018-04-12 2022-09-29 Jason Jingxi ZHANG Oligonucleotide compositions and methods of use thereof
WO2019217784A1 (en) * 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US20220186217A1 (en) * 2018-12-06 2022-06-16 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
CA3154768A1 (en) * 2019-10-06 2021-04-15 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof

Also Published As

Publication number Publication date
US20230089442A1 (en) 2023-03-23
JP2022525541A (ja) 2022-05-17
WO2020191252A1 (en) 2020-09-24
EP3941924A1 (en) 2022-01-26
KR20210149750A (ko) 2021-12-09
CA3134036A1 (en) 2020-09-24
AU2020241559A1 (en) 2021-11-11
BR112021018492A2 (pt) 2021-11-23
SG11202110045PA (en) 2021-10-28
EP3941924A4 (en) 2022-12-28
CN113748116A (zh) 2021-12-03
IL286487A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
MX2021011351A (es) Tecnologias utiles para la preparacion de oligonucleotidos.
EP4069281A4 (en) NEW ENZYMES
EP3980567A4 (en) DIRECT REDUCTION PROCESS USING HYDROGEN
MX2019010769A (es) Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos.
PH12015501953A1 (en) Substituted nucleotide analogs
AU2018258581A8 (en) RAF-degrading conjugate compounds
HK1203075A1 (en) Substituted phosphorothioate nucleotide analogs
MX2019011778A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
HK1250727A1 (zh) 视网膜色素变性的治疗
MX2019011758A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
EP3945848A4 (en) PROBIOTICS TO REDUCE METHANE PRODUCTION
MX2019008241A (es) Un enlazador polipeptídico para preparar anticuerpos multispecíficos.
MX344858B (es) Nuevo procedimiento para la síntesis de rifaximina y una nueva forma pseudocristalina de rifaximina obtenida con el mismo.
MY190551A (en) Method for preparing pyrrolo[3,2-d]pyrimidine compound, and intermediates thereof
WO2019224548A3 (en) Methods for the production of methacrylates
EP3962643A4 (en) CATALYSTS FOR HYDROGEN PRODUCTION
WO2013053857A3 (en) Gene cluster for biosynthesis of griselimycin and methylgriselimycin
MX2021011385A (es) Compuestos antineoplasicos.
EP4069835A4 (en) PROTHROMBIN PURIFICATION
MX2017014890A (es) Metodos de produccion de acetolactato-descarboxilasa (aldc).
WO2014170916A3 (en) Uricase mutants
WO2017051437A3 (en) A nucleotide sequence encoding 7-dehydrocholesterol reductase, recombinant constructs and recombinant organisms comprising said sequence
MX2017012733A (es) Produccion de compuestos fragantes.
TW201612142A (en) Process for preparing 3-chloro-2-vinylphenol
EP3815703A4 (en) PROMOTER OF PRODUCTION OF INTERLEUKIN-6, 10